Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 26Prostatic Neoplasms 5Stomach Neoplasms 3Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tongue Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bilateral Breast Carcinoma × ixabepilone × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡